185537-77-3

Upstream product

• 185537-68-2 (R)-3-methyl-5-phenyl-5 ,6-dihydro-2H-1,4-oxazin-2-one 
• 677-22-5 tert-butylmagnesium chloride 
• 56613-80-0 D-2-phenylglycinol 

Downstream Products

• 1207754-81-1 (3R,5R)-3-(1,1-dimethylethyl)-3-methyl-5-phenylmorpholin-2-one 
• 1207754-88-8 C₁₆H₂₃NO₂ 

Relevant academic research and scientific papers

1,3-β-Glucan synthase inhibitor Triterpenoid antifungal agent

Fungal pathogens are responsible for a large number of mild to severe infections worldwide resulting in 1.6 million deaths. With the rapid emergence of drug resistance, the treatment of fungal infections is rapidly becoming unmanageable. Thus, the discovery and development of novel antifungal drugs is an unmet need of the hour. In this context, ibrexafungerp (SCY-078; SCYNEXIS) is the first orally bioavailable agent that has activity against β-glucan synthase, an essential component of the cell wall. It has broad-spectrum activity against a wide range of Candida sp, including those that are resistant to echinocandins. In addition, ibrexafungerp exhibits broad-spectrum fungicidal activity including against multidrug-resistant strains, possesses high tissue penetration and exhibits flexible dosing options including via oral and intravenous routes. The U.S. Food and Drug Administration has granted both qualified infectious disease product and fast track designations for the oral formulation of ibrexafungerp for the treatment and prevention of recurrent vulvovaginal candidiasis.